BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12812665)

  • 41. Long-term follow-up of children treated with daclizumab for steroid-refractory gastrointestinal GvHD in a prospective study.
    Hamidieh AA; Hadjibabaie M; Ghehi MT; Jalili M; Hosseini A; Pasha F; Behfar M; Ghavamzadeh A
    Pediatr Transplant; 2012 Sep; 16(6):664-9. PubMed ID: 22738324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytokine gene expression in peripheral blood mononuclear cells and alloreactivity in hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL; Madsen HO; Ryder LP; Svejgaard A; Dickmeiss E; Vindeløv LL
    Biol Blood Marrow Transplant; 2006 Jan; 12(1):48-60. PubMed ID: 16399568
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptor.
    Tiley C; Powles R; Teo CP; Treleaven J; Findlay M; Hewetson M
    Bone Marrow Transplant; 1991; 7 Suppl 2():151. PubMed ID: 1652326
    [No Abstract]   [Full Text] [Related]  

  • 44. Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD.
    Perfetti P; Carlier P; Strada P; Gualandi F; Occhini D; Van Lint MT; Ibatici A; Lamparelli T; Bruno B; Raiola AM; Dominietto A; Di Grazia C; Bregante S; Zia S; Ferrari GM; Stura P; Pogliani E; Bacigalupo A
    Bone Marrow Transplant; 2008 Nov; 42(9):609-17. PubMed ID: 18660840
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients.
    Hui CH; Sia H; Mangos H; Horvath N; Lee H; Lewis I; Hughes T; To LB; Bardy P
    Bone Marrow Transplant; 2008 Feb; 41(4):409-10. PubMed ID: 18026147
    [No Abstract]   [Full Text] [Related]  

  • 46. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Huang XJ; Jiang Q; Chen H; Xu L; Liu D; Chen Y; Han W; Zhang Y; Liu K; Lu D
    Bone Marrow Transplant; 2005 Aug; 36(4):343-8. PubMed ID: 15968295
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A semi-pharmaceutical approach for the preparation of an anti-IL2 receptor monoclonal antibody in the treatment of acute GvHD in a multicentric study.
    Wijdenes J; Beliard R; Muot S; Herve P; Peters A
    Dev Biol Stand; 1990; 71():103-11. PubMed ID: 2205522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current and novel therapies in acute GVHD.
    Ho VT; Cutler C
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):223-37. PubMed ID: 18503988
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.
    Izumi N; Furukawa T; Sato N; Okazuka K; Tsukada N; Abe T; Yano T; Kurasaki T; Masuko M; Toba K; Takahashi M; Aizawa Y
    Bone Marrow Transplant; 2007 Nov; 40(9):875-80. PubMed ID: 17724440
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
    Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
    Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.
    Stelljes M; van Biezen A; Slavin S; Olavarria E; Clark RE; Nagler A; Koza V; Kienast J; Niederwieser D; de Witte T; Ruutu T;
    Bone Marrow Transplant; 2008 Dec; 42(11):739-42. PubMed ID: 18724394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nutritional support for patients suffering from intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Imataki O; Nakatani S; Hasegawa T; Kondo M; Ichihashi K; Araki M; Ishida T; Kim SW; Mori S; Fukuda T; Tobinai K; Tanosaki R; Makimoto A; Takaue Y
    Am J Hematol; 2006 Oct; 81(10):747-52. PubMed ID: 16865687
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD.
    Wawer A; Laws HJ; Dilloo D; Göbel U; Burdach S
    Klin Padiatr; 2004; 216(3):169-75. PubMed ID: 15175962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy.
    Creamer D; Martyn-Simmons CL; Osborne G; Kenyon M; Salisbury JR; Devereux S; Pagliuca A; Ho AY; Mufti GJ; du Vivier AW
    Arch Dermatol; 2007 Sep; 143(9):1157-62. PubMed ID: 17875877
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation.
    Lee KH; Choi SJ; Lee JH; Lee JS; Kim WK; Lee KB; Sohn SK; Kim JG; Kim DH; Seol M; Lee YS; Lee JH
    Haematologica; 2005 Jul; 90(7):939-48. PubMed ID: 15996932
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
    Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation.
    Herve P; Bordigoni P; Cahn JY; Flesch M; Tiberghien P; Racadot E; Milpied N; Bergerat JP; Plouvier E; Roche C
    Transplant Proc; 1991 Feb; 23(1 Pt 2):1692-4. PubMed ID: 1989333
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.